Ubiquitin Carboxy-Terminal Hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure by Mondello, Stefania et al.
 
 
 
This document has been downloaded from  
Tampub – The Institutional Repository of University of Tampere 
The permanent address of the publication is http://urn.fi/URN:NBN:fi:uta-
201212111087  
  
Author(s):  Mondello, Stefania; Palmio, Johanna; Streeter, Jackson; Hayes, Ronald L; Peltola, Jukka; Jeromin, Andreas 
Title:  Ubiquitin Carboxy-Terminal Hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure 
Year:  2012 
Journal Title:  BMC Neurology 
Vol and 
number:  12 : 85  
Pages:  1-7 
ISSN:  1471-2377 
Discipline:  Neurology and psychiatry 
School /Other 
Unit:  School of Medicine 
Item Type:  Journal Article 
Language:  en 
DOI:  http://dx.doi.org/doi:10.1186/1471-2377-12-85  
URN:  URN:NBN:fi:uta-201212111087 
URL:  http://www.biomedcentral.com/1471-2377/12/85  
 
  
  
  
  
All material supplied via TamPub is protected by copyright and other intellectual property rights, and 
duplication or sale of all part of any of the repository collections is not permitted, except that material 
may be duplicated by you for your research use or educational purposes in electronic or print form. 
You must obtain permission for any other use. Electronic or print copies may not be offered, whether 
for sale or otherwise to anyone who is not an authorized user. 
 
 
  
  
  
  
  
Mondello et al. BMC Neurology 2012, 12:85
http://www.biomedcentral.com/1471-2377/12/85RESEARCH ARTICLE Open AccessUbiquitin Carboxy-Terminal Hydrolase L1
(UCH-L1) is increased in cerebrospinal fluid and
plasma of patients after epileptic seizure
Stefania Mondello1,3*, Johanna Palmio2, Jackson Streeter1, Ronald L Hayes1, Jukka Peltola2 and Andreas Jeromin1*Abstract
Background: Clinical and experimental studies have demonstrated that seizures can cause molecular and cellular
responses resulting in neuronal damage. At present, there are no valid tests for assessing organic damage to the
brain associated with seizure. The aim of this study was to investigate cerebrospinal fluid (CSF) and plasma
concentrations of Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), a sensitive indicator of acute injury to brain
neurons, in patients with tonic–clonic or partial secondarily generalized seizures due to various etiologies.
Methods: CSF and plasma concentrations of UCH-L1 were assessed in 52 patients within 48 hours after epileptic
seizure and in 19 controls using ELISA assays.
Results: CSF obtained within 48 hours after seizure or status epilepticus (SE) presented significantly higher levels of
UCH-L1 compared to controls (p = 0.008). Plasma UCH-L1 concentrations were negatively correlated with time to
sample withdrawal. An analysis conducted using only the first 12 hours post-seizure revealed significant differences
between concentrations of UCH-L1 in plasma and controls (p = 0.025). CSF and plasma concentrations were
strongly correlated with age in patients with seizure, but not in control patients. Plasma UCH-L1 levels were also
significantly higher in patients after recurrent seizures (n = 4) than in those after one or two seizures (p = 0.013 and
p = 0.024, respectively).
Conclusion: Our results suggest that determining levels of neuronal proteins may provide valuable information on
the assessment of brain damage following seizure. These data might allow clinicians to make more accurate
therapeutic decisions, to identify patients at risk of progression and, ultimately, to provide new opportunities for
monitoring therapy and targeted therapeutic interventions.
Keywords: Biomarkers, UCH-L1, Epileptic seizures, Neuronal damageBackground
Epilepsy is a common acquired chronic neurological dis-
order occurring in ~1% of the general population. Recent
experimental studies have shown that seizures, whether
continuous or sporadic, can cause molecular and cellular
responses resulting in neuronal damage or death, gliosis,
and axonal and dendritic remodeling [1,2]. Although some
efforts have been made to identify biochemical markers in
CSF or blood of patients with epileptic seizure that could
assess organic damage or aid in the diagnosis and* Correspondence: smondello@banyanbio.com; ajeromin@banyanbio.com
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reproduction in any medium, provided the ormonitoring of disease progression, to date, none of those
markers has gained clinical importance [1,3,4].
Ubiquitin C-terminal hydrolase (UCH-L1) is a neuron-
specific cytoplasmic enzyme, highly enriched in neurons
[5]. Increased cerebrospinal fluid (CSF) and blood con-
centrations of UCH-L1 have been associated with pro-
cesses of neuron destruction (loss) and increased blood
brain barrier (BBB) permeability [6]. UCH-L1 concentra-
tion has been reported to be elevated in a number of
neurological diseases including aneurysmal subarachnoid
hemorrhage, traumatic brain injury (TBI), stroke and
neonatal hypoxic-ischemic encephalopathy (HIE) [7-10].
After TBI, blood UCH-L1 level correlates with injury se-
verity, outcome at discharge and 6 months after injuryral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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detected in CSF and blood very early after injury [11],
which provides a valuable time-window for potential
neuroprotective strategies. Because of its clinically rele-
vant characteristics and high brain specificity, UCH-L1
has been recently recognized as a novel and promising
biomarker of neuronal injury and BBB disruption.
To our knowledge, no studies have assessed UCH-L1
in patients after seizures. Therefore, the objective of the
present investigation was to evaluate CSF and plasma
concentrations of UCH-L1 in patients with tonic–clonic
or partial secondarily generalized seizures and their rela-
tionship to clinical characteristics including etiology and
number of seizures.
Methods
Subjects
This study enrolled a total of 52 patients with single or
recurrent tonic–clonic or partial secondarily general-
ized seizures admitted at the Emergency Department of
Neurology, Tampere University Hospital, Finland. The
study protocol was approved by the Ethics Committee
of Tampere University Hospital. Written informed con-
sent was obtained from all patients. This investigation
was part of an ongoing study aimed to assess biochemical
markers in patients with epileptic seizures. Forty-eight of
the patients evaluated in the present study and their bio-
chemical analyses have been previously reported else-
where [4].
Patients were classified according to the etiology of epi-
leptic seizures into alcohol withdrawal group (n = 15), acute
systemic illness or acute CNS disorder group (n = 6),Table 1 Demographic and clinical characteristics of patients w
Characteristic Epileptic Gr
Age, years, median (IQR) 45.5 (3
Male, n (%) 30 (5
Time to sampling, h 12.5 (7
Epilepsy Etiology
Alcohol Withdrawal 15 (2
Acute Systemic Illness or Acute CNS Disorder 6 (1
Remote Symptomatic Epilepsy 14 (2
Cryptogenic Focal 14 (2
Idiopathic Epilepsy 3 (5
Seizure Characteristic
One 27 (5
Two 11 (2
Three 1 (1
Four 4 (7
Status Epilepticus 9 (1
Mann–Whitney U-test for continuous variables, cross-tabulations and chi-square-tesremote symptomatic epilepsy group (n = 14) and
cryptogenic focal or idiopathic epilepsy group (n = 17).
Patient demographics and clinical characteristics are
given in Table 1. The etiology of acute systemic illness
or acute CNS disorder included sepsis, hyponatremia,
acute brain infarction, encephalitis and necrotizing en-
cephalomyelitis. The etiology of remote symptomatic epi-
lepsy included brain tumor (n = 5), post-stroke or post-
traumatic epilepsy (n = 6), Alzheimer’s disease (n = 1),
multiple sclerosis (n = 1), and post-encephalitic epilepsy
(n = 1). Patients with cryptogenic focal or idiopathic epi-
lepsy did not present any abnormal finding on computed
tomography (CT) or magnetic resonance imaging (MRI)
of the brain. CSF and venous blood samples were taken
within 48 h after the seizure (median 12.5 hrs).
We included a control population consisting of 19
individuals without history of central nervous system
disease or seizures on whom lumbar was performed to
exclude neurological disorders. Neurological examin-
ation, neuroimaging (CT or MRI of the head) and la-
boratory analysis showed normal results for all controls
(Table 1).
UCH-L1 determination
Approximately 15 mL of CSF and 5 mL of plasma were
collected from each subject. Samples were centrifuged
for 10 minutes at 4000 rpm and immediately frozen and
stored at −70°C until the time of analysis. All samples
were analyzed in duplicate. Samples were measured
using a standard UCH-L1 sandwich ELISA protocol as
described below. Reaction wells were coated with cap-
ture antibody (500 ng/well purified anti-rabbit UCHL1,ith epileptic seizure and controls
oup (n = 52) Controls (n = 19) P value
1.5-62) 41 (32–45) 0.13
7.69) 4 (21.05) 0.014*
–20) -
8.85) -
1.54) -
6.92) -
6.92) -
.77) -
1.92) -
1.15) -
.92) -
.69) -
7.31) -
t for categorical variables.
Table 2 CSF and plasma concentration of UCH-L1 in patients with seizure and in controls
N Epileptic Group (n = 52) N Controls (n = 19) P-value
After seizure CSF UCH-L1 51 0.934 (0.513-1.582) 13 0.627 (0.234-0.723) 0.008*
Plasma UCH-L1 33 0.163 (0.119-0.253) 16 0.145 (0.116-0.192) 0.2
Within 12 hrs after seizure CSF UCH-L1 26 1.300 (0.55-1.822) 0.005*
Plasma UCH-L1 16 0.186 (0.154-0.286) 0.025†
Data are given as median (interquartile range).
* p < 0.01, † p < 0.05 (p values of the Mann–Whitney test for differences between the groups [patients versus controls]).
Figure 1 UCH-L1 concentration in CSF and plasma of patients
within 48 hrs and within 12 hrs after seizure and in controls.
The red horizontal line represents the median. Significant differences
are indicated with * (P < .05) (Mann–Whitney U-test).
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incubated overnight at 4°C. Plates were then emptied out
and 300 μl/well blocking buffer (Startingblock T20-TBS)
was added and incubated for 30 min at ambient temperature
with gentle shaking. This was followed by addition of anti-
gen standard (UCHL1 standard curve: 0.05 - 50 ng/well)
unknown samples (3–10 uL CSF) or assay internal control
samples. The plate was incubated for 2 hours at room
temperature then washed using an automatic plate washer
(each well rinsed with 5 x 300 μl with wash buffer (TBST)).
Detection antibody (anti-rabbit UCH-L1-HRP conjugation,
made in-house at 50 μg/mL) in blocking buffer was then
added to wells at 100 μl/well and the plates were further
incubated for 1.5 hours at room temperature. After
additional automatic washing, biotinyl-tyramide solu-
tion (Perkin Elmer Elast Amplification Kit) was added
and the plate was incubated for 15 minutes at room
temperature followed by automatic washing. Addition
of Streptavidin-HRP (1:500, 100ul/well) in PBS with
0.02% Tween 20 and 1% BSA for 30 minutes incubation
at room temperature preceded automatic washing.
Lastly, the wells were developed with substrate solu-
tion: Ultra-TMB ELISA 100ul/well (Pierce# 34028) with
incubation for 5–30 minutes and read at 652 nm with a
96- well spectrophotometer (Molecular Device Spectra-
max 190).
Statistical analysis
All statistical analyses were performed using SAS (SAS
version [9.2] of the SAS System. Copyright © 2002–2008
by SAS Institute Inc., Cary, NC, USA). Exploratory ana-
lysis was carried out to determine the distribution of the
data. Continuous variables are presented as mean (SD) or
median (interquartile range), as appropriate. Distributions
of categorical variables are presented as frequencies and
percentages. Categorical variables were compared using
the chi-square or Fisher’s exact test, as appropriate. The
Mann–Whitney test was used to compare biomarker con-
centrations between two groups and the Kruskal-Wallis
test was used in case of three or more groups. Spearman
rank correlation test was used to test correlations between
biomarkers and continuous variables. All hypothesis tests
conducted were 2-tailed. A p value < 0.05 was considered
significant.Results
A total of 52 patients and 19 controls were included for
analyses. As indicated in Table 1, the characteristics of
patients and controls were similar except for the gender:
58% of subjects with seizure compared with 21% of con-
trols were male. UCH-L1 concentrations in CSF were
significantly higher in patients within 48 hrs after epilep-
tic seizure than in controls. Plasma UCH-L1 concentra-
tions were similar in both study groups. The median
value and interquartile range of UCH-L1 for patients
with epileptic seizure and for controls are shown in
Table 2 (Figure 1). Furthermore, plasma UCH-L1 con-
centrations were negatively correlated with time to
sample withdrawal (R = −0.38, P =0.029), but no correla-
tions with UCH-L1 in CSF were found. An analysis con-
ducted using only the first 12 hours post-seizure showed
significant differences between concentrations of UCH-L1
in plasma and control group (p =0.025) as well as in CSF
and controls (p = 0.005) (Table 2, Figure 1).
CSF and plasma levels of UCH-L1 were not affected
by sex. UCH-L1 in CSF and plasma were strongly corre-
lated with age in patients with seizure, but not in
Figure 2 UCH-L1 concentration in CSF and plasma and age in patients with epileptic seizure. Biomarkers were positively correlated with
age in patients with epileptic seizure. Linear regression line and 95% CI were given (on the right) (n = 51).
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concentrations were positively correlated with plasma
concentrations (R = 0.38, P =0.030).
The number of seizures showed significant differences
also for concentration of UCH-L1 in plasma. Patients
with recurrent seizures (n = 4) had significantly higher
plasma UCH-L1 concentrations than patients with one or
two seizures (median, 0.38 vs 0.15 vs 0.18 ng/ml, p = 0.013
and p = 0.024, respectively) (Figure 3). CSF UCH-L1 con-
centrations did not differ between these subpopulations,
but a trend of increasing number of seizures was observed
(data not shown).
Discussion
A series of experimental studies from multiple laborator-
ies have provided evidence for the association of epilepsy
with brain damage and have shown that seizures can in-
duce neuronal loss [12-14]. These findings were also
confirmed in humans. In particular, previous studies
examining brain tissue resected for the treatment of
drug-refractory epilepsy have indicated that recurrent
generalized seizures and long duration of epilepsy are
associated with severe neuronal loss [15-18]. Seizure-
induced neuronal death has been reported to result pri-
marily from excitotoxicity that leads to DNA damage
and protease activation, culminating in necrosis [19], but
activation of programmed (apoptotic) cell death path-
ways following seizures has also been found [20,21]. Bio-
chemical markers identifying neuronal damage or loss
associated with injury have been sought. Increased levels
of neuron-specific enolase (NSE), a marker of neuronal
damage, has been demonstrated in CSF and serum ofTable 3 Spearman correlation coefficient (p value)
between biomarker concentrations and demographic
variable
Age
Patients with seizures Controls
CSF UCH-L1 0.70 (<.0001)* 0.21 (0.74)
Plasma UCH-L1 0.55 (0.0025)* −0.6 (0.28)both children and adult patients after spontaneous and
evoked epileptic seizures, but the findings were not con-
sistent and very few risk factors for increased NSE levels
have been identified [3,22-28].
UCH-L1 has previously been identified as neuronal
cell body injury by our and others groups in a number
of different neurological conditions [7-11,29]. The focus
of the current study was to evaluate the concentration of
UCH-L1 in CSF and plasma of patients in the acute
phase after epileptic seizures (median interval between
epileptic seizure and sample collection 12.5 h).
We found that elevated UCH-L1 concentrations occur
in CSF of patients within 48 hrs after epileptic seizure.
In addition, our study showed that increased plasma
UCH-L1 concentrations are found within 12 h but not
within 48 after epileptic seizure. This observation has 2
major implications. First, UCH-L1 seems to detect
damage at a very early time point after seizure whenFigure 3 Plasma UCH-L1 concentration in patients within
48 hrs after single or recurrent seizures, or status epilepticus.
The red horizontal line represents the median. Significant differences
are indicated with * (P < .05) (Mann–Whitney U-test).
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fective. Second, this finding might be explained by the
fact that elevated plasma UCH-L1 reflects disruption of
the BBB during the acute phase after seizure. Indeed,
previous reports have suggested that prolonged seizure
activity in animals and humans, as well as the occur-
rence of brief, induced, and spontaneous seizures, may
be associated with opening of the BBB [30-32]. This con-
sideration is also supported by the negative correlation be-
tween UCH-L1 plasma concentrations and time to sample
withdrawal.
Remarkably, patients with recurrent seizures had higher
UCH-L1 levels in plasma than patients with single event
and UCH-L1 levels increased with the number of seizures
(Figure 3). Supporting these observations, a number of ex-
perimental studies have provided compelling evidence of
an association between recurrent seizures and neuronal
loss in animals [13-15,33] and histological analysis has
indicated that as the number of seizures increases, the
damage becomes more severe [13,14]. In humans, histo-
logical findings [16,18,34] as well as sensitive imaging
techniques have provided evidence that seizure frequency
is associated with the severity of structural brain damage
[35-38]. Kälviäinen et al. [36], however, suggest that a large
number of seizures are needed to result in structural dam-
age detectable by neuroimaging (MRI), while individual
seizures cause relatively limited damage involving a small
number of neurons that may be easily overlooked or re-
main undetected. Therefore, the detection of damage
caused by a single seizure in vivo challenges the resolution
of anatomical or imaging techniques. As a consequence,
the cumulative seizure-induced structural damage result-
ing from subtle but recurring insults may take decades be-
fore becoming evident along with the slowly evolving
cognitive decline associated with the damage which may
be difficult to detect in clinical practice until an advanced
status. Therefore, biochemical markers such as UCH-L1
are necessary and may represent an extremely sensitive
method for the assessment of mild damage following seiz-
ure and a simple but critical way to monitor the progres-
sion of the disorder.
Two important promising characteristics of UCH-L1
should be noted: the half-life (ranging from 7 to 9 hours,
in CSF and serum, respectively) [11] and a prompt detec-
tion soon after injury (within 3 hours, in our study). In-
deed, the rapid appearance associated with a rapid
elimination allows assessment of the amount of seizure-
related brain damage and, by using repeated measure-
ments, makes it possible to distinguish between this injury
and other chronic and underlying conditions or secondary
injuries. Furthermore, when the assay is ported to a point-
of-care (POC) system, accurate results will be available to
the clinician with a short turnaround time (within 30 min
or less), [39] allowing rapid ED assessment.Additionally, the increased UCH-L1 levels observed
after recurrent seizure may reflect the continuing mo-
lecular, cellular, or network changes and neuronal
reorganization associated with the recurring and cumu-
lative damage responsible for the long-term alterations
in neural circuits and progression of the disorder.
Interestingly, CSF and plasma UCH-L1 concentrations
showed a strong correlation with age in patients with
seizures but no correlation was found in controls. To-
gether, these data suggest that age may influence the
severity of seizure-related damage and, therefore, the re-
lease of brain-specific markers into the CSF and through
the BBB into the circulation. Consistently, previous stud-
ies did not find neuronal loss when generalized seizures
were induced in immature animals suggesting an early
developmental resistance to seizure-induced damage
[40-43]. An age-dependent increase in brain damage
after seizures was also reported in humans [17]. Never-
theless, it is important to note that previous studies have
shown that, even in the absence of overt neuronal injury,
immature brain undergoes neuronal reorganization after
recurrent seizures with mossy fiber sprouting, asymmet-
ric synapses and neurogenesis [42,43]. In addition, pro-
longed seizures have been shown occasionally to produce
acute injury in children that has evolved to hippocampal
atrophy [44]. Therefore, for clinical use, including the
pediatric setting, a multimarker strategy could be the most
promising and accurate approach in refining risk stratifi-
cation among children with acute epileptic seizures by
providing information on the cell type and subcellular
localization of injury as well as on the biochemical path-
ways and underlying physiology of cell death that can re-
sult in progression of the disorder.
Our study has several limitations. No accurate data were
available regarding seizure duration. The time interval be-
tween seizure, lumbar puncture and plasma sampling var-
ied. However, the sampling was performed at the earliest
time point available after admission and not more than
48 hrs after seizure. Furthermore, our cohort represents
heterogeneous etiologies of epileptic seizures. These vari-
ables may reflect different features of the underlying dis-
ease process and its damaging effects. We emphasize that
further studies addressing the relationship between neur-
onal damage and BBB disruption following seizure are
needed. However, the intent of this exploratory study was
to investigate the potential role of UCH-L1 as a putative
biomarker of neuronal injury and BBB dysfunction in
patients after seizure in an emergency department, where
this information could be critical to improve the manage-
ment and guide a timely and effective treatment.
Conclusion
This study presents the first results of increased CSF
and plasma concentrations of UCH-L1 in patients after
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evaluate the utility of UCH-L1 as a surrogate marker for
brain damage in epilepsy. We believe that the identifica-
tion of CNS-specific proteins, providing important insight
into underlying mechanisms and damage following
seizure, could support the choice of timely and effective
treatments tailored to the clinical situation and reveal new
opportunities for intervention and drug development.
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